Market Overview

BMO Valeant Reaction: 10-K Could Give Investors Confidence To Value Shares Above $60

Related VRX
Valeant's High Debt Load Puts Q4 Focus On EBITDA Guidance
Watch These 8 Huge Call Purchases In Monday Trade
Valeant beefs up salesforce, 250 reps and managers hired in three months (Seeking Alpha)

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are selling off on Monday afternoon, following a higher morning amid news that the company will move on from its current CEO. The stock is still up 6 percent on the day. While Wall Street's reaction is mixed, one analyst is giving his thoughts on what Valeant's next catalyst could be.

'The most important upcoming event for VRX is the filing of its 10-K, which the company expects by April 29, 2016," BMO's Alex Arfaei wrote. "If Valeant is able to do this, it will cure the technical default in its covenants. At that point, investors should have a better handle on the underlying fundamentals of this business."

In Arfaei's opinion, Valeant is undervalued based on its actual fundamentals, but investors don't care about that at the moment because of high levels of uncertainty. "To get back to fundamentals, in our view Valeant needs to rebuild credibility first," he added. That starts with replacing CEO Mike Pearson and asking former CFO Howard Schiller to resign from the Board -- two updates the company announced on Monday.

"Investor confidence should then follow with execution," the analyst predicted.

Valeant's target price at BMO is $66 per share, a 145 percent return potential as of Arfaei's writing. The stock presently trades near $29 per share.

Latest Ratings for VRX

Dec 2016Morgan StanleyDowngradesOverweightEqual-Weight
Nov 2016MizuhoDowngradesNeutralUnderperform
Nov 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Health Care Analyst Ratings Movers Trading Ideas


Related Articles (VRX)

View Comments and Join the Discussion!